BGM vs. CCCC, VYGR, YMAB, MBIO, ACIU, HRTX, AMLX, NGNE, ATAI, and DMAC
Should you be buying Qilian International Holding Group stock or one of its competitors? The main competitors of Qilian International Holding Group include C4 Therapeutics (CCCC), Voyager Therapeutics (VYGR), Y-mAbs Therapeutics (YMAB), Mustang Bio (MBIO), AC Immune (ACIU), Heron Therapeutics (HRTX), Amylyx Pharmaceuticals (AMLX), Neurogene (NGNE), Atai Life Sciences (ATAI), and DiaMedica Therapeutics (DMAC). These companies are all part of the "pharmaceutical products" industry.
Qilian International Holding Group vs.
C4 Therapeutics (NASDAQ:CCCC) and Qilian International Holding Group (NASDAQ:BGM) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, media sentiment, profitability, community ranking, valuation, earnings and institutional ownership.
C4 Therapeutics has a beta of 2.96, indicating that its stock price is 196% more volatile than the S&P 500. Comparatively, Qilian International Holding Group has a beta of 1.52, indicating that its stock price is 52% more volatile than the S&P 500.
C4 Therapeutics received 27 more outperform votes than Qilian International Holding Group when rated by MarketBeat users.
Qilian International Holding Group has a net margin of 0.00% compared to C4 Therapeutics' net margin of -313.35%. Qilian International Holding Group's return on equity of 0.00% beat C4 Therapeutics' return on equity.
C4 Therapeutics currently has a consensus target price of $10.67, indicating a potential upside of 177.06%. Given C4 Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe C4 Therapeutics is more favorable than Qilian International Holding Group.
In the previous week, C4 Therapeutics had 1 more articles in the media than Qilian International Holding Group. MarketBeat recorded 1 mentions for C4 Therapeutics and 0 mentions for Qilian International Holding Group. C4 Therapeutics' average media sentiment score of 0.02 beat Qilian International Holding Group's score of 0.00 indicating that C4 Therapeutics is being referred to more favorably in the media.
Qilian International Holding Group has higher revenue and earnings than C4 Therapeutics.
78.8% of C4 Therapeutics shares are held by institutional investors. 8.6% of C4 Therapeutics shares are held by company insiders. Comparatively, 58.7% of Qilian International Holding Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Summary
C4 Therapeutics beats Qilian International Holding Group on 9 of the 15 factors compared between the two stocks.
Get Qilian International Holding Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for BGM and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Qilian International Holding Group Competitors List
Related Companies and Tools
This page (NASDAQ:BGM) was last updated on 1/22/2025 by MarketBeat.com Staff
